Cargando…
Optimized TrkB Agonist Ameliorates Alzheimer’s Disease Pathologies and Improves Cognitive Functions via Inhibiting Delta-Secretase
[Image: see text] BDNF/TrkB neurotropic pathway, essential for neural synaptic plasticity and survival, is deficient in neurodegenerative diseases including Alzheimer’s disease (AD). Our previous works support that BDNF diminishes AD pathologies by inhibiting delta-secretase, a crucial age-dependent...
Autores principales: | Chen, Chun, Ahn, Eun H., Liu, Xia, Wang, Zhi-Hao, Luo, Shilin, Liao, Jianming, Ye, Keqiang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical Society
2021
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8269693/ https://www.ncbi.nlm.nih.gov/pubmed/34106682 http://dx.doi.org/10.1021/acschemneuro.1c00181 |
Ejemplares similares
-
Deficiency in BDNF/TrkB Neurotrophic Activity Stimulates δ-Secretase by Upregulating C/EBPβ in Alzheimer’s Disease
por: Wang, Zhi-Hao, et al.
Publicado: (2019) -
Delta-secretase cleavage of Tau mediates its pathology and propagation in Alzheimer’s disease
por: Kang, Seong Su, et al.
Publicado: (2020) -
A TrkB agonist prodrug prevents bone loss via inhibiting asparagine endopeptidase and increasing osteoprotegerin
por: Xiong, Jing, et al.
Publicado: (2022) -
Therapeutic potential of a TrkB agonistic antibody for Alzheimer's disease
por: Wang, Shudan, et al.
Publicado: (2020) -
Do Small Molecules Activate the TrkB Receptor in the Same Manner as BDNF? Limitations of Published TrkB Low Molecular Agonists and Screening for Novel TrkB Orthosteric Agonists
por: Pankiewicz, Piotr, et al.
Publicado: (2021)